GlassScriptPhysician profile
Saima Khurram
NPI 1710149455
$27,526.60
in general payments reported to CMS, 2019-2025
73 companies · $4,423 in 2025
The $4,423 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,658 · 2020: $2,757 · 2021: $5,537 · 2022: $3,379 · 2023: $4,100 · 2024: $4,672 · 2025: $4,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,023.47 |
| Education | $171.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,868.36 | 2019-2025 | |
| Ucb, INC. | $2,222.84 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Catalyst Pharmaceuticals, INC. | $1,668.49 | 2019-2025 | Fycompa |
| Novartis Pharmaceuticals Corporation | $1,307.75 | 2019-2025 | |
| Biogen, INC. | $1,233.35 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Amneal Pharmaceuticals LLC | $1,200.83 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $996.12 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $982.37 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $805.08 | 2019-2024 | Mavenclad |
| Neurelis, INC. | $803.13 | 2020-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $757.31 | 2019-2025 | Ultomiris |
| Mdd US Operations, LLC | $726.41 | 2019-2025 | Gocovri, Gocovri, Qelbree |
| Allergan, INC. | $624.79 | 2019-2022 | |
| Lilly USA, LLC | $597.88 | 2019-2025 | Amyvid, Kisunla |
| Pfizer INC. | $588.28 | 2021-2025 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Khurram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.